Is now the right time to invest in the stock?
Our score explained
Indicators
Catalyst Potential
About
Insider Trading
About
Insider activity in Ultimovacs has been in neutral territory for the past six months
Shares sold
Shares bought
0-1
months
1-3
months
3-6
months
Unusual event signals:
Do you want access to the underlying factors of the Timeliness score? Try Redeye premium, starting at SEK 99/month. Gain insight from upcoming triggers, relative strength, insider trading and more with Timeliness.
Already a member?
Sign in
Earnings Revisions
About
No significant revisions in current and next year’s earnings estimates (up 10% or more) by Redeye’s analyst in the last 30 days
Earnings Trend
About
Ultimovacs shows no significant positive change in quarterly earnings (EPS) growth
No trend
Upside/Downside Volume
About
Ultimovacs’s up/down volume ratio of -- (below 1.0) indicates negative demand for the stock over the past 50 days
Ultimovacs’s 20 day up/down volume ratio is below its 50-day trailing ratio, indicating decreasing demand for the stock
Price Trend
About
Ultimovacs’s 20-day moving average price is below the 50-day measure, indicating a bearish short-term trend
Ultimovacs’s 20-day moving average price is below the 200-day measure, indicating a bearish long-term trend
Ultimovacs’s stock price is not trading close to its 52-week high, which is a strong momentum indicator
Relative Strength
About
Ultimovacs’s 26-week price performance is down -- (>0%) relative to the market (OMXSPI)
Ultimovacs’s last 13-week relative price performance compared to the market is weaker than the previous 13-week period
Ultimovacs’s 26-week price performance is down -- (>0%) relative to its sector peers
Stock Price
OMXSPI